Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Immunity Pharma Reports Positive Phase 2a Results for IPL344 in ALS Patients
Details : IPL344 is a peptide that stimulates therapeutic cell signaling and is under phase 2 development for amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 17, 2024
Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS
Details : In this early stage clinical trial, disease progression rate during IPL344 treatment was about 50% slower than expected without treatment, in both functional and respiratory endpoints. The drug also demonstrated a very favorable safety and tolerability p...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 09, 2020
A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 27, 2018
Lead Product(s) : IPL344
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of IPL344 in the Treatment of ALS Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 29, 2018
Lead Product(s) : IPL344
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
